The company noted that if the FDA approves its application, Imosidolimab could address a significant unmet medical need in this rare and life-threatening disorder.
Looking ahead, CEO Gayn Erickson said he expects nearly all of the company’s served markets to experience order growth in the fiscal year, with silicon carbide growth expected to strengthen further in the next fiscal year.
The private-equity firm has been actively pursuing software deals, with the firm striking a $12.3 billion deal to acquire human resources management software firm Dayforce last week.
IWM gained 4.6% in a month as small caps show signs of life, narrowing the gap with large caps after a long slump. Is this the start of a winning trend or just a short-term rebound?